-
1.Substituted piperazines,(1,4) diaszepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists 失效
标题翻译: 作为组胺h1和/或h3拮抗剂或组胺h3反向拮抗剂的取代的哌嗪,(1,4)二氮杂和2,5-二氮杂双环(2.2.1)公开(公告)号:US20060025404A1
公开(公告)日:2006-02-02
申请号:US10531758
申请日:2003-10-14
申请人: Rachel Ancliff , Colin Eldred , Yvonne Fogden , Ashley Hancock , Thomas Heightman , Heather Hobbs , Simon Hodgson , Matthew Lindon , David Wilson
发明人: Rachel Ancliff , Colin Eldred , Yvonne Fogden , Ashley Hancock , Thomas Heightman , Heather Hobbs , Simon Hodgson , Matthew Lindon , David Wilson
IPC分类号: A61K31/551 , A61K31/496
CPC分类号: C07D213/81 , C07D209/42 , C07D211/46 , C07D213/50 , C07D213/64 , C07D215/40 , C07D215/46 , C07D215/50 , C07D239/28 , C07D243/08 , C07D265/36 , C07D277/62 , C07D285/06 , C07D295/088 , C07D295/185 , C07D295/192 , C07D295/215 , C07D295/26 , C07D307/79 , C07D307/85 , C07D311/84 , C07D317/68 , C07D333/38 , C07D405/06 , C07D487/08 , C07D491/04
摘要: The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.
摘要翻译: 本发明涉及具有药理活性的新颖的哌嗪和吖庚因衍生物,其制备方法,含有它们的组合物及其在治疗包括阿尔茨海默病的神经变性疾病中的用途。
-
公开(公告)号:US20060019964A1
公开(公告)日:2006-01-26
申请号:US11112048
申请日:2005-04-22
申请人: Ranchael Ancliff , Colin Eldred , Yvonne Fogden , Ashley Hancock , Thomas Heightman , Heather Hobbs , Simon Hodgson , Matthew Lindon , David Wilson
发明人: Ranchael Ancliff , Colin Eldred , Yvonne Fogden , Ashley Hancock , Thomas Heightman , Heather Hobbs , Simon Hodgson , Matthew Lindon , David Wilson
IPC分类号: A61K31/496 , C07D403/02
CPC分类号: C07D211/46
摘要: 1-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}-4-{[4-(methylsulfonyl)phenyl]carbonyl}piperazine or a derivative thereof.
摘要翻译: 1- {4 - [(1-环丁基-4-哌啶基)氧基]苯基} -4 - {[4-(甲基磺酰基)苯基]羰基}哌嗪或其衍生物。
-
3.Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain 失效
标题翻译: 异恶唑脲衍生物作为治疗疼痛的vr-1受体调节剂公开(公告)号:US20050107388A1
公开(公告)日:2005-05-19
申请号:US10505358
申请日:2003-03-21
申请人: Rebecca Brown , Victoria Doughty , Gregory Hollingworth , A. Jones , Matthew Lindon , Christopher Moyes , Lauren Rogers
发明人: Rebecca Brown , Victoria Doughty , Gregory Hollingworth , A. Jones , Matthew Lindon , Christopher Moyes , Lauren Rogers
IPC分类号: C07D237/28 , A61K31/427 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/502 , A61K31/506 , A61K31/5377 , A61P1/04 , A61P11/00 , A61P11/06 , A61P13/10 , A61P19/02 , A61P19/06 , A61P25/02 , A61P25/04 , A61P25/06 , A61P29/00 , A61P37/02 , C07D215/38 , C07D217/02 , C07D217/08 , C07D217/14 , C07D217/16 , C07D217/22 , C07D217/24 , C07D217/26 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D417/14 , A61K31/541 , A61K31/496 , A61K31/498 , A61K31/517
CPC分类号: C07D401/12 , C07D215/38 , C07D217/02 , C07D217/08 , C07D405/12 , C07D413/12 , C07D417/12
摘要: The present invention provides compounds of formula (I); pharmaceutically acceptable salts and N-oxides thereof in which A, B, D and E are C or N with the proviso that one or more are N, R1, R2, R3, R4, R5 and R6 are simple substituents, n is 0-3 and y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; as VR-1 antagonists for treating conditions or diseases in which pain and/or inflammation predominates; the use of the same for manufacturing medicaments, pharmaceutical compositions comprising them and methods of treatment utilising them.
摘要翻译: 本发明提供式(I)化合物; 其中A,B,D和E为C或N的药学上可接受的盐和N-氧化物,条件是一个或多个为N,R 1,R 2, R 3,R 4,R 5和R 6是简单的取代基,n是0-3和 y是芳基,杂芳基,碳环基或稠合碳环基; 作为用于治疗其中疼痛和/或炎症占优势的病症或疾病的VR-1拮抗剂; 使用它们制造药物,包含它们的药物组合物和使用它们的治疗方法。
-
-